This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 33.72% and 5.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More
by Kinjel Shah
Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $38.22 in the latest trading session, marking a -1.01% move from the prior day.
Editas (EDIT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
by Zacks Equity Research
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
Editas (EDIT) Down on Initial Data From Eye Disease Study
by Zacks Equity Research
Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.
Implied Volatility Surging for Editas (EDIT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas (EDIT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.